The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888 · see citing works

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · see citing works

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · see citing works

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · see citing works

The Physiology of Glucagon-like Peptide 1

Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · see citing works

Comparative quantification of health risks : global and regional burden of disease attributable to selected major risk factors

Ezzati, M., López, A. D., Rodgers, A., & Murray, C. J. L. (2004) · Cited by 3,319 · see citing works

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death

The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726 · see citing works

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · see citing works

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

Turner, R. C., Millns, H., Neil, H. A. W., Stratton, I. M., Manley, S. E., Matthews, D. R., & Holman, R. R. (1998) · BMJ · doi:10.1136/bmj.316.7134.823 · Cited by 2,014 · see citing works

Basal insulin and cardiovascular and other outcomes in dysglycemia

The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · see citing works

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · see citing works

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes

and the WHO Multinational Study Group, Morrish, N. J., Wang, S.-L., Stevens, L. K., Fuller, J. H., & Keen, H. (2001) · Diabetologia · doi:10.1007/pl00002934 · Cited by 1,288 · see citing works

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works

Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study

Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · see citing works

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · see citing works

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · see citing works

Risk Factors for Renal Dysfunction in Type 2 Diabetes

Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., Holman, R. R., & for the UKPDS Study Group (2006) · Diabetes · doi:10.2337/db05-1620 · Cited by 927 · see citing works

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · see citing works

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · see citing works

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 790 · see citing works

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · see citing works

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · see citing works

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation

Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 1× · see citing works

Association of Overweight With Increased Risk of Coronary Heart Disease Partly Independent of Blood Pressure and Cholesterol Levels<subtitle>A Meta-analysis of 21 Cohort Studies Including More Than 300 000 Persons</subtitle>

Bogers, R. P. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.16.1720 · Cited by 656 · see citing works

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · see citing works

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · see citing works

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study

Buse, J. B., Nauck, M., Forst, T., Sheu, W. H.-H., Shenouda, S. K., Heilmann, C. R., Hoogwerf, B. J., Gao, A., Boardman, M. K., Fineman, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61267-7 · Cited by 565 · see citing works

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen, A. B., Jørgensen, E. O., Helqvist, S., Saunamäki, K. I., Clemmensen, P. M., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr309 · Cited by 550 · see citing works

Exenatide and the treatment of patients with Parkinson's disease

Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529 · see citing works

Cardiovascular Biology of the Incretin System

Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 527 · see citing works

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · see citing works

Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury

Timmers, L., Henriques, J. P. S., de Kleijn, D. P. V., DeVries, J. H., Kemperman, H., Paul Steendijk, A., Verlaan, C. W. J., Kerver, M., Piek, J. J., Doevendans, P. A., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.033 · Cited by 471 · see citing works

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457 · see citing works

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434 · see citing works

Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · see citing works

Entry of exendin-4 into brain is rapid but may be limited at high doses

Kastin, A., & Akerstrom, V. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 362 · see citing works

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4

Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · see citing works

Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347 · see citing works

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice

Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · see citing works

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

Gallwitz, B., Rosenstock, J., Rauch, T., Bhattacharya, S., Patel, S. D., von Eynatten, M., Dugi, K. A., & Woerle, H. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60691-6 · Cited by 339 · see citing works

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Russell-Jones, D. L., Cuddihy, R. M., Hanefeld, M., Kumar, A., González‐González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2011) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 334 · see citing works

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326 · see citing works

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

Dore, D. D., Seeger, J. D., & Chan, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 324 · see citing works

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin

Garg, R., Chen, W. C., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 319 · see citing works

Enhanced Risk for Alzheimer Disease in Persons With Type 2 Diabetes and APOE ε4

Irie, F., Fitzpatrick, A. L., López, O. L., Kuller, L. H., Peila, R., Newman, A. B., & Launer, L. J. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.29 · Cited by 304 · see citing works

Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome

Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276 · see citing works

The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide

Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273 · see citing works

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

Shiraki, A., Oyama, J.-I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.039 · Cited by 263 · see citing works

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · see citing works

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · see citing works

ABC of arterial and venous disease: Vascular complications of diabetes

Donnelly, R. (2000) · BMJ · doi:10.1136/bmj.320.7241.1062 · Cited by 258 · see citing works

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program

Armstrong, M. J., Houlihan, D. D., Rowe, I. A., Clausen, W. H. O., Elbrønd, B., Gough, S. C. L., Tomlinson, J. W., & Newsome, P. N. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12149 · Cited by 250 · see citing works

Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial

Marso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., Pocock, S., Steinberg, W. M., Bergenstal, R. M., Mann, J. F. E., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.012 · Cited by 244 · see citing works

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240 · see citing works

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

Rosenstock, J., Klaff, L. J., Schwartz, S., Northrup, J., Holcombe, J. H., Wilhelm, K., & Trautmann, M. (2010) · Diabetes Care · doi:10.2337/dc09-1203 · Cited by 229 · see citing works

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

Åhrén, B., JOHNSON, S. L., Stewart, M. W., Cirkel, D. T., Yang, F., Perry, C., & Feinglos, M. N. (2014) · Diabetes Care · doi:10.2337/dc14-0024 · Cited by 228 · see citing works

Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Cuthbertson, D. J., Irwin, A., Gardner, C. J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E. L., Adams, V. L., Pushpakom, S. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050117 · Cited by 226 · see citing works

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

Monami, M., Dicembrini, I., Martelli, D., & Mannucci, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.602964 · Cited by 217 · see citing works

Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia

Lønborg, J., Kelbæk, H., Vejlstrup, N., Bøtker, H. E., Kim, W. Y., Holmvang, L., Jørgensen, E. O., Helqvist, S., Saunamäki, K. I., Terkelsen, C. J., et al. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.112.968388 · Cited by 210 · see citing works

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

on behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210 · see citing works

Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210 · see citing works

Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients

Gaglia, J. L., Guimaraes, A. R., Harisinghani, M., Turvey, S. E., Jackson, R., Benoist, C., Mathis, D., & Weissleder, R. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44339 · Cited by 209 · see citing works

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE -/- mouse model

Gaspari, T. A., Liu, H., Welungoda, I., Hu, Y., Widdop, R. E., Knudsen, L. B., Simpson, R. W., & Dear, A. E. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111404257 · Cited by 203 · see citing works

Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis

Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191 · see citing works

A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer

Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186 · see citing works

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

Horowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · see citing works

Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight

Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Knudsen, L. B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 175 · see citing works

Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease

Driver, J. A., Smith, A., Buring, J. E., Gaziano, J. M., Kurth, T., & Logroscino, G. (2008) · Diabetes Care · doi:10.2337/dc08-0688 · Cited by 168 · see citing works

Pancreatic Volume Is Reduced in Adult Patients with Recently Diagnosed Type 1 Diabetes

Williams, A. J. K., Thrower, S., Sequeiros, I. M., Ward, A., Bickerton, A. S. T., Triay, J., Callaway, M. P., & Dayan, C. M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1815 · Cited by 166 · see citing works

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljanski, J. I., Sapin, H., TRAUTMANN, M. E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 158 · see citing works

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Ratner, R. E., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. Z. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 152 · see citing works

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes — Relationship to postprandial glycemia

Lorenz, M., Pfeiffer, C., Steinstraesser, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 147 · see citing works

Exenatide as a Weight‐Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study

Kelly, A. S., Metzig, A. M., Rudser, K. D., Fitch, A., Fox, C. K., Nathan, B. M., Deering, M. M., Schwartz, B. L., Abuzzahab, M. J., Gandrud, L. M., et al. (2011) · Obesity · doi:10.1038/oby.2011.337 · Cited by 143 · see citing works

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats

Han, W.-N., Hölscher, C., Yuan, L., Yang, W., Wang, X., Wu, M., & Qi, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.009 · Cited by 138 · see citing works

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

Gill, A. M., Hoogwerf, B. J., Burger, J., BRUCE, S. R., MacConell, L., Yan, P., Braun, D. K., Giaconia, J. M., & Malone, J. K. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-6 · Cited by 134 · see citing works

Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results

Madsbad, S. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.008 · Cited by 128 · see citing works

Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes

Sathyanarayana, P., Jogi, M., Muthupillai, R., Krishnamurthy, R., Samson, S. L., & Bajaj, M. (2011) · Obesity · doi:10.1038/oby.2011.152 · Cited by 124 · see citing works

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 123 · see citing works

Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus

White, W. B., Pratley, R. E., Fleck, P. R., Munsaka, M., Hisada, M., Wilson, C., & Menon, V. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12093 · Cited by 117 · see citing works

Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice

Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 112 · see citing works

Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide ( HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin

Reusch, J. E. B., Stewart, M. W., Perkins, C. M., Cirkel, D. T., Ye, J., Perry, C., Reinhardt, R., & Bode, B. W. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12382 · Cited by 110 · see citing works

Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency

Bao, W., Aravindhan, K., Alsaid, H., Chendrimada, T. P., Szapacs, M. E., Citerone, D. R., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023570 · Cited by 105 · see citing works

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

Marso, S. P., Lindsey, J. B., Stolker, J. M., House, J. A., Ravn, G. M., Kennedy, K. F., Jensen, T. M., & Buse, J. B. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111408937 · Cited by 103 · see citing works

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme

Niswender, K. D., Pi‐Sunyer, X., Buse, J. B., Jensen, K. H., Toft, A. D., Russell-Jones, D. L., & Zinman, B. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01673.x · Cited by 100 · see citing works

Exenatide-Associated Ischemic Renal Failure

Weise, W. J., Sivanandy, M. S., Block, C. A., & Comi, R. J. (2009) · Diabetes Care · doi:10.2337/dc08-1309 · Cited by 99 · see citing works

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

Kelly, A. S., Bergenstal, R. M., Gonzalez-Campoy, J., Katz, H., & Bank, A. J. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-64 · Cited by 98 · see citing works

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety

Nathanson, D., Ullman, B., Löfström, U., HEDMAN, A. G., Frick, M., Sjöholm, Å., & Nyström, T. (2012) · Diabetologia · doi:10.1007/s00125-011-2440-x · Cited by 96 · see citing works

New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer’s disease?

Hölscher, C., & Li, L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.023 · Cited by 93 · see citing works

The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges

Davies, M. J. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802745 · Cited by 92 · see citing works

Glucagon‐like peptide‐1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study

Ahern, T., Tobin, A., Corrigan, M., Hogan, A. E., Sweeney, C. M., Kirby, B., & O'Shea, D. B. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04609.x · Cited by 91 · see citing works

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

Flint, A., Kapitza, C., Hindsberger, C., & Zdravkovic, M. (2011) · Advances in Therapy · doi:10.1007/s12325-010-0110-x · Cited by 91 · see citing works

Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats

Liu, W. J., Jin, H. Y., Lee, K. A., Xie, S. H., Baek, H. S., & Park, T. S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01272.x · Cited by 84 · see citing works

Mild Renal Impairment and the Efficacy and Safety of Liraglutide

Davidson, J. A., Brett, J., Falahati, A., & Scott, D. (2010) · Endocrine Practice · doi:10.4158/ep10215.or · Cited by 84 · see citing works

Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.

Egefjord, L., Gejl, M., Møller, A., Brændgaard, H., Gottrup, H., Antropova, O., Møller, N., Poulsen, H. E., GJEDDE, A. H., Brock, B., et al. (2012) · PubMed · Cited by 80 · see citing works

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

Cobble, M. E., & Frederich, R. C. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-6 · Cited by 78 · see citing works

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti‐diabetic medication: a follow‐up study

Wenten, M., Gaebler, J. A., Hussein, M. A., Pelletier, E. M., Smith, D. B., Girase, P. G., Noel, R. A., Braun, D. K., & Bloomgren, G. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03652.x · Cited by 75 · see citing works

Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function

Forst, T., Michelson, G., Ratter, F., Weber, M. M., Anders, S., Mitry, M., Wilhelm, B., & Pfützner, A. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03589.x · Cited by 75 · see citing works

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

Wohlfart, P., Linz, W., Hübschle, T., Linz, D., Huber, J., Hess, S., Crowther, D., Werner, U., & Ruetten, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-84 · Cited by 75 · see citing works

Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research

Irace, C., Luca, S. D., Shehaj, E., Carallo, C., Loprete, A., Scavelli, F. B., & Gnasso, A. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112449562 · Cited by 72 · see citing works

Exendin-4 Protected against Cognitive Dysfunction in Hyperglycemic Mice Receiving an Intrahippocampal Lipopolysaccharide Injection

Huang, H.-J., Chen, Y., Liang, K., Jheng, Y.-S., Jhao, J.-J., Su, M., Lee‐Chen, G., & Hsieh‐Li, H. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039656 · Cited by 71 · see citing works

Anti‐inflammatory effects of exendin‐4, a glucagon‐like peptide‐1 analog, on human peripheral lymphocytes in patients with type 2 diabetes

He, L., Wong, C. K., Cheung, K. K., Yau, H. C., Fu, A., Zhao, H., Leung, K. M., Kong, A. P., Wong, G. W., Chan, P. K., et al. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12063 · Cited by 70 · see citing works

Magnetic resonance imaging: a reliable method for measuring pancreatic volume in Type 1 diabetes

Williams, A. J. K., Chau, W., Callaway, M. P., & Dayan, C. M. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02027.x · Cited by 67 · see citing works

Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes

Davies, M. J., Kela, R., & Khunti, K. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 66 · see citing works

Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology

Drucker, D. J., & Rosen, C. F. (2011) · Diabetologia · doi:10.1007/s00125-011-2297-z · Cited by 66 · see citing works

Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide

Faurschou, A., Knop, F. K., Thyssen, J. P., Zachariae, C., Skov, L., & Vilsbøll, T. (2014) · Acta Diabetologica · doi:10.1007/s00592-011-0359-9 · Cited by 65 · see citing works

Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiation

Punjabi, M., Arnold, M., Geary, N., Langhans, W., & Pacheco‐López, G. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.02.038 · Cited by 62 · see citing works

Improvement of psoriasis during exenatide treatment in a patient with diabetes

Buysschaert, M., Tennstedt, D., & Preumont, V. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.004 · Cited by 57 · see citing works

Incretin Therapy and Islet Pathology: A Time for Caution

Kahn, S. E. (2013) · Diabetes · doi:10.2337/db13-0520 · Cited by 57 · see citing works

Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK–eNOS pathways

Han, L., Yu, Y., Sun, X., & Wang, B. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.04.001 · Cited by 55 · see citing works

Liraglutide‐Induced Acute Kidney Injury

Kaakeh, Y., Kanjee, S., Boone, K., & Sutton, J. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1014 · Cited by 54 · see citing works

Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once‐Daily Human GLP‐1 Analog for Treatment of Type 2 Diabetes

Chatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R., & Litwin, J. S. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009339189 · Cited by 54 · see citing works

Endothelial dysfunction – A predictor of atherosclerosis

Chhabra, N. (2009) · Internet Journal of Medical Update - EJOURNAL · doi:10.4314/ijmu.v4i1.39872 · Cited by 49 · see citing works

Psoriasis increased the risk of diabetes: a meta-analysis

Cheng, J., Kuai, D., Zhang, L., Yang, X., & Qiu, B. (2011) · Archives of Dermatological Research · doi:10.1007/s00403-011-1200-6 · Cited by 46 · see citing works

Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: The EXAMI study

Bernink, F. J. P., Timmers, L., Diamant, M., Scholte, M., Beek, A. M., Otto Kamp, B., Marques, K. M., Denham, R. N., Chen, W. J. Y., Doevendans, P. A., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.204 · Cited by 46 · see citing works

Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers

López-Ruiz, A., Peso-Gilsanz, C., Meoro-Avilés, A., Soriano-Palao, J., Andreu, A., Cabezuelo, J., & Arias, J. L. (2010) · Pharmacy World & Science · doi:10.1007/s11096-010-9423-8 · Cited by 44 · see citing works

Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter

Valensi, P. E., Chiheb, S., & Fysekidis, M. (2013) · Diabetologia · doi:10.1007/s00125-013-2909-x · Cited by 41 · see citing works

Acute tubulointerstitial nephritis following treatment with exenatide

Nandakoban, H., Furlong, T., & Flack, J. (2013) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03738.x · Cited by 40 · see citing works

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects

Darpö, B., Sager, P. T., MacConell, L., Cirincione, B. B., Mitchell, M. I., Han, J., Huang, W., Malloy, J. L., Schulteis, C. T., Shen, L. Z., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04416.x · Cited by 35 · see citing works

A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects

Linnebjerg, H., Seger, M. E., Kothare, P. A., Hunt, T. L., Wolka, A. M., & Mitchell, M. I. (2011) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201462 · Cited by 32 · see citing works

Exenatide Once-Weekly Clinical Development: Safety and Efficacy Across a Range of Background Therapies

Stonehouse, A., Walsh, B., & Cuddihy, R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0076 · Cited by 26 · see citing works

Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

Scott, L. J. (2013) · BioDrugs · doi:10.1007/s40259-013-0057-y · Cited by 24 · see citing works

Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study

Goldstein, B. J., Weissman, P. N., Wooddell, M. J., Waterhouse, B. R., & Cobitz, A. R. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x115720 · Cited by 19 · see citing works

Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells

Erdogdu, Ö., Eriksson, L., Nyström, T., et al. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.02.106 · Cited by 19 · see citing works

Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes

Wick, A., & Newlin, K. (2009) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2009.00455.x · Cited by 13 · see citing works

Association of Exenatide With Liver Enzymes in Patients With Type 2 Diabetes

Bulchandani, D. G., Nachnani, J. S., Eaton, C., & Hamburg, M. S. (2009) · The Endocrinologist · doi:10.1097/ten.0b013e3181a48938 · Cited by 6 · see citing works

Efficacy and Safety of Dulaglutide Versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1)

Wysham, C., Blevins, T., Arakaki, R. F., et al. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.08.126 · Cited by 6 · see citing works

Abstract 1004: Administration Of A Glucagon-like Peptide-1 Receptor Agonist Prevents Cardiac Rupture And Increases Survival In Mice Undergoing Myocardial Infarction

Noyan-Ashraf, M. H., Sadi, A.-M., Momen, M. A., et al. (2007) · Circulation · Cited by 2 · see citing works

1.5 Efficacy and Safety of Dulaglutide vs. Metformin in Type 2 Diabetes (AWARD-3) (69-OR)

Umpierrez, G. E., Manghi, F. P., Tofé, S., et al. (2013) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-013-0030-x · Cited by 2 · see citing works

OP03 Effects of two years of liraglutide treatment on fatty liver disease in patients with type 2 diabetes: analysis of the Liraglutide Effect and Action in Diabetes-2 extension trial

Armstrong, M., Falahati, A., Houlihan, D. D., Elbrand, B., Schmidt, W. E., Gough, S. C. L., & Newsome, P. N. (2010) · Gut · doi:10.1136/gut.2010.223362.3 · Cited by 2 · see citing works

Abstract 19477: The Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Reduces Inflammation and Improves Cardiac Function in a Mouse Model of Obesity

Noyan-Ashraf, M. H., Billia, F., Mukovozov, I., et al. (2010) · Circulation · Cited by 1 · see citing works

1.2 Efficacy and Safety of Dulaglutide versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1) (66-OR)

Wysham, C., Blevins, T., Arakaki, R. F., et al. (2013) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-013-0027-5 · Cited by 1 · see citing works

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

Yao, H., Zhang, A., Li, D., Wu, Y., Wang, C.-Z., Wan, J.-Y., & Yuan, C.-S. (2024) · BMJ · doi:10.1136/bmj-2023-076410 · Cited by 558 · see citing works

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463 · see citing works

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383 · see citing works

Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications

Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358 · see citing works

Reasons for Discontinuation of GLP1 Receptor Agonists: Data from a Real-World Cross-Sectional Survey of Physicians and Their Patients with Type 2 Diabetes

Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223 · see citing works

Epicardial adipose tissue GLP-1 receptor is associated with genes involved in fatty acid oxidation and white-to-brown fat differentiation: a target to modulate cardiovascular risk?

Dozio, E., Vianello, E., Malavazos, A. E., Tacchini, L., Schmitz, G., Iacobellis, G., & Corsi Romanelli, M. M. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.04.039 · Cited by 118 · see citing works

<scp>GLP</scp> ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond

Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112 · see citing works

Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice

Zhu, T., Wu, X.-L., Zhang, W., & Xiao, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920195 · Cited by 106 · see citing works

GLP-1 agonists: A review for emergency clinicians

Long, B., Pelletier, J., Koyfman, A., & Bridwell, R. E. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.01.010 · Cited by 67 · see citing works

Recent advances in understanding the role of glucagon-like peptide 1

Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66 · see citing works

Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis

Masson, W., Lobo, M., Nogueira, J. P., Rodriguez-Granillo, A. M., Barbagelata, L. E., & Siniawski, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1379189 · Cited by 57 · see citing works

Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein

Zhou, W., Shao, W., Zhang, Y., Liu, D., Liu, M., & Jin, T. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00292.2020 · Cited by 36 · see citing works

Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double‐blind, placebo‐controlled phase <scp>3a</scp> clinical trial

Shuai, Y., Yang, G., Zhang, Q., Li, W., Luo, Y., Ma, J., Chen, D., Yang, J., Wang, X., Hu, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14198 · Cited by 35 · see citing works

GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance

Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35 · see citing works

Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors

Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24 · see citing works

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis

Cignarelli, A., Genchi, V. A., Le Grazie, G., Caruso, I., Marrano, N., Biondi, G., D’Oria, R., Sorice, G. P., Natalicchio, A., Perrini, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.846903 · Cited by 24 · see citing works

Is liraglutide or exenatide better in type 2 diabetes?

Doggrell, S. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903264051 · Cited by 2 · see citing works

Use of exenatide and liraglutide in Denmark: a drug utilization study

Pottegård, A., Bjerregaard, B. K., Larsen, M. D., Larsen, K. S., Hallas, J., Knop, F. K., & Moreno, S. I. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1595-4 · Cited by 12 · see citing works

Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.

(2010) · PubMed

P-1405 Glycaemic control improves in type 2 diabetes patients when switching from twice-daily exenatide to once-daily liraglutide

Buse, J. B., Sesti, G., Schmidt, W. E., et al. (2009) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(09)33267-0

Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus

Santoleri, F., Sorice, P., Lasala, R., & Costantini, A. (2014) · Pharmacology &amp Pharmacy · doi:10.4236/pp.2014.54040 · Cited by 3 · see citing works